Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease

Table 1

Study characteristics.

Study	Raju et al.	Deftereos et al.	LoDoCo	COLIN	LoDoCo-MI	COLCOT	LoDoCo-2	COPS
Countries	Canada	Greece	Australia	France	Australia	12 countries	Australia and Netherlands	Australia
Total no. of Pts	82	222	532	44	237	4745	5522	795
Year	2012	2013	2013	2017	2019	2019	2020	2020
Population	ACS or acute ischemic stroke	Diabetes, age 40–80, undergoing PCI with a BMS	Clinically stable CAD for ≥6 months	STEMI	MI	MI	Chronic CAD	ACS
Colchicine dose	1 mg once daily	0.5 mg twice daily	0.5 mg once daily	1 mg once daily	0.5 mg daily	0.5 mg daily	0.5 mg daily	0.5 mg twice daily for 1 month, followed by 0.5 mg once daily for 11 months
Comparator	Placebo	Placebo	Usual care	Usual care	Placebo	Placebo	Placebo	Placebo
Duration of therapy (months)	1	6	24	1	1	19.6	Not specified	12
Follow-up (months)	1	6	36	1	1	22.6	28.6	13.3
Primary outcome	hs-CRP level	In-stent restenosis	ACS, OHCA, or noncardioembolic ischemic stroke	CRP peak value during index hospitalization	hs-CRP level ≥2 mg/L	CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization	CV death, MI, ischemic stroke, or ischemia-driven coronary revascularization	All-cause mortality, ACS, unplanned urgent revascularization, or noncardioembolic ischemic stroke
Source of funding	Academic	Not specified	Academic	None	Academic	Academic	Academic	Academic

ACS: acute coronary syndrome; BMS: bare metal stent; CAD: coronary artery disease; CRP: C-reactive protein; CV death: cardiovascular death; hs-CRP: high-sensitivity C-reactive protein; MACE: major adverse cardiovascular events; MI: myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.